ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02482324
Recruitment Status : Completed
First Posted : June 26, 2015
Last Update Posted : July 21, 2015
Sponsor:
Collaborators:
Panax Clinical Research
Pharma Consulting Group AB
KCAS
Information provided by (Responsible Party):
AZTherapies, Inc.

Brief Summary:
This is an open-labeled, cross-over design, pharmacokinetic study, to determine the pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and ALZT-OP1b, in both plasma and CSF, following co-administration of the active compounds, in healthy volunteers, aged 55-75, and in good general health.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: ALZT-OP1a Drug: ALZT-OP1b Device: Dry Powder Inhaler Phase 1

Detailed Description:

This is an open-labeled, cross-over design, pharmacokinetic study, where 24 subjects will be randomly assigned to receive treatment regimen A-B or B-A on two consecutive days of dosing.

Two dosing groups are planned for the study :

  • Group 1 (n=12)
  • Group 2 (n=12)

Each group will be admitted to the Phase I Unit the evening before dosing and will initiate dosing the next morning for 2-days of consecutive treatment (A-B, or B-A). Both groups will undergo identical study related procedures, except those subjects that consent to CSF collection on Day 1 of dosing.

Dose regimen A consists of a single inhaled oral dose of ALZT-OP1a via dry powder inhaler + a single oral tablet dose of ALZT-OP1b.

Dose regimen B consists of two oral inhaled doses of ALZT-OP1a, not more than 2 minutes apart, via dry powder inhaler + two oral tablet doses of ALZT-OP1b.

Plasma Collection, All Subjects (n=24) 1 mL blood samples will be collected at T: 0, 5, 10, 15, 30, 1 hr, 2 hr, 4 hr, and 6 hours, following ALZT-OP1 administration (Days 1 and 2).

CSF Collection, Sub-group (n=12) A sub-group of 12 subjects will be consented for CSF collection.

1 mL of CSF will be collected at T: 0, 5 min, 30 min, 2 hr, and 4 hours, following ALZT-OP1 administration (Day 1 only).


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Phase I, Randomized, Open-Labeled Pharmacokinetic Study of ALZT-OP1 in Normal Healthy Volunteers
Study Start Date : June 2015
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Arm Intervention/treatment
Treatment A-B
12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
Drug: ALZT-OP1a
Mast cell stabilizer
Other Name: Cromolyn, Intal

Drug: ALZT-OP1b
anti-inflammatory
Other Name: ibuprofen

Device: Dry Powder Inhaler
The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.

Treatment B-A
12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
Drug: ALZT-OP1a
Mast cell stabilizer
Other Name: Cromolyn, Intal

Drug: ALZT-OP1b
anti-inflammatory
Other Name: ibuprofen

Device: Dry Powder Inhaler
The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.




Primary Outcome Measures :
  1. Non-compartmental plasma pharmacokinetics for ALZT-OP1a and ALZT-OP1b [ Time Frame: T=0 to 6 hours (0, 5, 10, 15, 30, 60, 120, 240, and 360 minutes) ]
    • AUC (0-∞) (area under the curve from 0 to infinity)
    • AUC (0-t) (area under the curve from 0 to t hours where t is the last measured concentration
    • AUCPLASMA/AUCCSF (ratio at 5 min, 30 min, 2 hr and 4 hours)
    • CL/F (apparent total body clearance)
    • Cmax (maximum plasma concentration observed)
    • T ½ (half life)
    • Tmax (sampling time at which Cmax occurred)
    • Vd/F (apparent volume of distribution

    Plasma concentration-time profiles will be presented for both study drugs.



Secondary Outcome Measures :
  1. Levels of ALZT-OP1a and ALZT-OP1b in cerebrospinal fluid (CSF) [ Time Frame: T=0 to 4 hours (0, 5, 30, 120, and 240 minutes) ]
    CSF samples will be collected at 5 time-points to measure levels of ALZT-OP1a and ALZT-OP1b in CSF.

  2. Number of Treatment Emergent Adverse Events (TEAE) [ Time Frame: 2 days ]
    Safety will be evaluated based on the number, type, and frequency of treatment emergent adverse events. They will be individually presented for all subjects in data listings, and summarized in tables by treatment group and by treatment assignment. The AEs will be summarized and reported collectively based on information obtained through physical examination, ECG, and laboratory findings captured after dosing was initiated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provide a signed written informed consent;
  • Age 55-75 inclusive;
  • ECG within normal limits;
  • Body mass index (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2;
  • Negative urine drug screen for selected drugs of abuse at screening;
  • Negative for hepatitis and HIV at screening;
  • Good general health, as determined by medical history, physical examination, and clinical laboratory testing;
  • Willingness to stay in the unit overnight for the duration of the study;
  • Consent for CSF collection (for those in CSF group).

Exclusion Criteria:

  • Current smokers, or ex-smokers with a remote history (> 100 pack/year);
  • Clinically significant medical conditions;
  • History of ECG abnormalities;
  • Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing;
  • Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in absence of febrile episodes, in the last 14 days;
  • History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism, and excretion of drugs;
  • Malignancy, regardless of location;
  • Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis;
  • Investigational agents are prohibited one month prior to entry and for the duration of the trial;
  • Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);
  • Currently taking cromolyn, or have taken cromolyn, within the past 30 days;
  • NSAID use (products containing ibuprofen while on study);
  • Aspirin, or products containing aspirin, while on study;
  • Allergy or hypersensitivity to cromolyn (also known as Intal®, Nasalcrom®, etc.);
  • Allergy or hypersensitivity to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin, including Stevens-Johnson syndrome;
  • History of hypersensitivity or allergies to any of the drug compound under investigation (cromolyn, ibuprofen, lactose, or magnesium stearate);
  • History of clinically significant respiratory disorders and chronic respiratory disease with impaired respiratory effort or difficulty taking inhaled drugs (examples: COPD, emphysema);
  • Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC < 70% of the predicted value for the subject, when compared to reference values; AND FEV1 and FVC < 70% of predicted value when compared to reference values, indicating moderate to severe respiratory obstruction;
  • Any other disease or condition, which, in the opinion of the investigator, would make the subject unsuitable for this study;
  • Female subjects of reproductive potential with a positive pregnancy test (urine or serum) or who are pregnant or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02482324


Locations
United States, Florida
Panax Clinical Research
Miami Lakes, Florida, United States, 33014
Sponsors and Collaborators
AZTherapies, Inc.
Panax Clinical Research
Pharma Consulting Group AB
KCAS
Investigators
Study Chair: David Elmaleh, PhD Study Sponsor
Study Director: David Brazier, BS Study Sponsor

Responsible Party: AZTherapies, Inc.
ClinicalTrials.gov Identifier: NCT02482324     History of Changes
Other Study ID Numbers: AZT-002
First Posted: June 26, 2015    Key Record Dates
Last Update Posted: July 21, 2015
Last Verified: July 2015